The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
Pregnant patients with MPN face an increased risk of bleeding. At what stage of the pregnancy is the risk of venous thromboembolism highest?
A
B
C
D
There is a distinct set of challenges for patients who become pregnant and have a diagnosis of myeloproliferative neoplasms (MPN), as previously discussed on the MPN Hub. These patients have an increased risk of thrombosis and hemorrhage, especially during delivery and postpartum, in addition to consequences for fetal growth, including placental insufficiency, stillbirth, and premature delivery.1 As a result, complex management strategies are required to ensure the best possible maternal and fetal outcomes. Best practice recommendations for managing pregnant patients with MPN have previously been reported on the MPN Hub. Here, we outline common risks, challenges, and further practice recommendations in the management of this patient population.
Figure 1. Management strategies according to pregnancy stage in patients with MPN*
LMWH, low molecular weight heparin; MPN, myeloproliferative neoplasms.
*Adapted from Robinson and Harrison.2
Pregnant patients diagnosed with MPN require multidisciplinary management to ensure the strategies associated with each stage of pregnancy are implemented and optimized. While maternal and fetal outcomes are improving with current therapeutic options and risk-mitigating recommendations, further advancement and refinement of management strategies is warranted.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content